We're working on something new at CrunchBase. Edits have been disabled for a few days, but you can still contact us for urgent changes.
Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

DescriptionGrowth equity - healthcare


ebut Health-Care Fund, 1/2013 $100M
Foresite Capital Fund II, L.P., 4/2014 $300M


San Francisco, USA
101 California Street, Suite 4100
San Francisco, CA, 94111


Founder & Managing Director
Managing Director
Managing Director
Managing Director
CFO & Managing Director
Founding CEO


Foresite Capital

Foresite Capital provides growth equity to healthcare companies with disruptive, late-stage products or services in high-growth markets with proven management teams who have a track record of building and leading. Since inception in 2011, Foresite has made four investments: Puma Biotechnology (NYSE: PBYI), Intarcia, Tarsa and Solta (NASDAQ: SLTM)

Recent Milestones


Company Date Round Size Participants
Nexvet 4/2014Series B$31.5M4
Intarcia Therapeutics 4/2014Private Equity$200M6
SAGE Therapeutics 3/2014Series C$38M5
Karyopharm Therapeutics 7/2013Series B$19M3
Sequenta 7/2013Series C$20M3
Tarsa Therapeutics 3/2012Series B$28M4



  1. Growth-Equity Firm Foresite Capital Raises $100M for Debut Health-Care Fund (pevc.dowjones.com) [edit]
  2. Foresite Capital Closes $300 Million Fund II to Finance Late-Stage Healthcare Companies Read more: Foresite Capital Closes $300 Million Fund II to Finance Late-Stage Healthcare Companies - FierceBiotech http://www.fiercebiotech.com/press-releases/foresit (fiercebiotech.com) [edit]
  3. Biotech Intarcia Raises 210M (online.wsj.com) [edit]
  4. Nexvet Biopharma Closes US$31.5M Series B Financing (finsmes.com) [edit]
  5. Intarcia Therapeutics Raises $200m Financing (finsmes.com) [edit]
  6. SAGE Therapeutics Completes $38M Series C Financing (finsmes.com) [edit]
  7. Cancer Drug Developer Karyopharm Adds $19M in Series B Extension (pevc.dowjones.com) [edit]
  8. Sequenta completes $20m Series C financing (finsmes.com) [edit]
  9. Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin (prnewswire.com) [edit]
Edit This Page
Last Edited 4/16/14

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy